Maravai LifeSciences Holdings, Inc. MRVI Latin and Central America — Revenue
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Maravai LifeSciences Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Maravai LifeSciences Holdings, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Maravai LifeSciences Holdings, Inc.'s latin and central america — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Maravai LifeSciences Holdings, Inc.'s latin and central america — revenue?
- Maravai LifeSciences Holdings, Inc. (MRVI) reported latin and central america — revenue of $329K in Q1 2026.
- How has Maravai LifeSciences Holdings, Inc.'s latin and central america — revenue changed year-over-year?
- Maravai LifeSciences Holdings, Inc.'s latin and central america — revenue increased by 125.3% year-over-year, from $146K to $329K.
- What is the long-term trend for Maravai LifeSciences Holdings, Inc.'s latin and central america — revenue?
- Over 4 years (2021 to 2025), Maravai LifeSciences Holdings, Inc.'s latin and central america — revenue has grown at a 3.6% compound annual growth rate (CAGR), from $842K to $971K.
- What does latin and central america — revenue mean?
- This metric represents the total gross sales generated from customers located within the Latin and Central American geographic region. It reflects the company's market penetration and demand for its life sciences products, including nucleic acid production and biologics safety testing, within this specific territory. Monitoring this revenue stream helps investors assess the company's international growth strategy and the geographic diversification of its customer base.